Monday, December 31, 2007

New year price hikes, as if on cue

ANYONE with an air conditioner should cherish the relief today because the cost of running it is going to rise substantially in the new year.

Like the fireworks at midnight, we could set our watches by the price rises that herald the new year, and along with electricity, the cost of public transport, toll booths and health care will rise.

Energy bills will be the most significant of the new year price rises for Victorian consumers.

On January 1, Victoria's three biggest energy retailers — Origin Energy, AGL and TRUenergy — will charge up to 17% more for power, after the drought, increased demand and renewable energy targets pushed the cost of generating electricity to record highs.

An average household paying $945 annually for its power bill is likely to pay $1106 for consuming 6500 kilowatt hours of peak and off-peak electricity. A larger family could face a rise of about $220 annually.

Riding trams, trains and buses will be more expensive in January, with the the cost of public transport in Melbourne rising by about 20 cents per trip, with a zone 1, two-hour full fare going from $3.30 to $3.50, and a zone 1-and-2, two-hour ticket rising from $5.30 to $5.50.

And you will not escape the price rises by taking the car, with Citylink passes set to rise by 4.5%, with an e-tag day pass going up to $5.97 and a 24-hour pass rising to $11.45.

Health too, will get more expensive.

The amount you have to spend to be eligible for the Medicare Safety Net — under which the Government picks up 80% of medical costs after you've spent a certain amount in a year — will rise by $9.80 to $529.30 for concession card holders and $19.70 to $1058.70 for general patients.

It will also be harder to qualify for the Pharmaceutical Benefits Scheme safety net. The threshold for general patients will rise $82.80 to $1141.80 and for concession card holders it will go up $15.60 to $290.

The amount patients will have to contribute to the cost of subsidised medicines will go up 60 cents to $31.30 for general patients and 10 cents to $5 for concession card holders.

But it is not all bad news.

Several new drugs will attract subsidies from tomorrow, including Champix for those quitting smoking and Alimta for the asbestos-related cancer mesothelioma.

And it will be easier to get eye treatment, with optometrists given the right to prescribe certain subsidised medications for the first time.


Source


Friday, December 28, 2007

State funeral for Bernie Banton

Bernie Banton, the public face of the campaign against asbestos company James Hardie, has died, but his efforts have been hailed as a decades-long legacy for asbestos disease sufferers.

Mr Banton, 61, died at his Sydney home about 1am (AEDT) on Tuesday with his family by his side.

His wife Karen, brother Bruce, sister Grace and five children have accepted the NSW government's offer of a state funeral.

Mr Banton was diagnosed in August with peritoneal mesothelioma, an abdominal cancer caused by his exposure to asbestos when he worked for a subsidiary of James Hardie from 1968 to 1974.

He had already been suffering for years from asbestosis, a lung disease also caused by exposure to asbestos.

Despite this, he led the campaign to force James Hardie to establish a fund that would provide adequate compensation for all its employees suffering from diseases caused by their exposure to asbestos at its factories.

He was, NSW Premier Morris Iemma said, "a truly great Australian, a man who fought for others at a time when he should have been worrying about his own health".

"In November 2006, on the day we signed the final agreement to secure compensation for Hardie victims (workers in James Hardie factories who contracted diseases caused by asbestos), Bernie knew he'd achieved something special.

"That deal was worth $1.5 billion over the next 40 years for those who suffered and continue to suffer this dreadful disease.

"It would not have been possible without Bernie Banton."

Prime Minister-elect Kevin Rudd said he was "a fighter" who was "a symbol, a living symbol of what is right and decent and proper in the workplace relations of this country".

"Australia is going to be poorer for Bernie's passing - our whole nation will be poorer for Bernie's passing," Mr Rudd said.

Mr Banton was diagnosed in 1999 with asbestosis and ARPD (asbestos-related pleural disease), which reduced his lung capacity to 40 per cent.

He began to rely on an oxygen bottle, but he refused to let it slow him down, taking it with him everywhere he went as he campaigned for fair compensation from James Hardie for all its affected workers.

Estimates of future claims continued to rise, and the company was eventually forced in December 2004 to sign Australia's largest ever compensation settlement, worth up to $4.5 billion over 40 years.

In a statement, James Hardie expressed its condolences to the family of Mr Banton, acknowledging his work in raising public awareness of asbestos-related disease.

"The company acknowledges the significant contribution Mr Banton made to raising the awareness of asbestos-related diseases in Australia, and his role in the eventual implementation of the final funding agreement to compensate Australians with asbestos-related personal injury claims," the company said.

NSW parliament rose for a moment's silence and both sides of politics delivered statements praising him.

"Bernie courageously pursued justice for sufferers of asbestos-related diseases and their families, we all owe him a debt of gratitude," NSW Industrial Relations Minister John Della Bosca said.

Former ACTU secretary Greg Combet said Mr Banton had been a fighter for other people and a fighter for justice.

"I hope that people properly appreciate the importance of the settlement that was reached with James Hardie a few years back, because it was a very hard fight and Bernie contributed a lot," Mr Combet said.

"That's how he should be recognised."

Last Thursday, Mr Banton won a confidential payout as compensation for his terminal mesothelioma, including exemplary damages for what his lawyers called James Hardie's "contumelious" disregard for the health of its workers when they knew of the dangers of asbestos.

In 2000, he had been awarded $800,000 compensation for asbestosis.

And last month he succeeded in getting the palliative drug Alimta subsidised by the federal government for mesothelioma sufferers.

His brother Bruce said Mr Banton's funeral would probably be held on Saturday but details were still being discussed.

"One thing we will be asking is for instead of flowers at the service is donations for asbestos research and treatments," he said.

In a further tribute, the Asbestos Diseases Research Institute at Sydney's Concord hospital will also be named the Bernie Banton Centre.

In Melbourne, he was honoured at a commemorative service, part of Asbestos Awareness Week, to remember people who have died from asbestos-related diseases.

Source



Victims of asbestos fight payout 'apartheid'

People suffering from pleural plaques through exposure to asbestos will soon be facing a postcode lottery to determine whether they qualify for compensation.

Pleural plaques are a scarring on the lining of the lungs, an asymptomatic sign of exposure to asbestos that does not of itself lead to more serious asbestos-related conditions. While about 1,800 people die of asbestos-related diseases each year in Britain, a number that is rising, some commentators have labelled plaques sufferers as 'the worried well' and the House of Lords recently ruled that the condition was not worthy of compensation.

'When people say those things, it's because they haven't had to live with it,' says Valerie Pask, a 55-year-old mother of seven from Nottingham who was diagnosed with plaques last year. Asbestos has left its mark on three generations of her family. 'I'll never forget my eldest brother in the final weeks before he died,' she recalls. 'He was unable to say more than a few words because his lungs were so congested.'

Valerie's brother died from mesothelioma, the cancer contracted from breathing in asbestos dust. Her father worked all his life as a lagger, fitting insulation at power stations. He died of heart disease in 1980, at the age of 65, with his death certificate recording that the condition was 'related to asbestosis'. 'My eldest brother, Brian, died at the age of 50 in 1987 and my next eldest brother, Michael, died in 1991,' she says. Three sons worked with their father. Two of them had their lives cut short by mesothelioma and the surviving brother was recently diagnosed with asbestosis. Her brother-in-law and sister-in-law, who worked with them, have both died of asbestos-related conditions, as did an uncle who worked in London.

But the tragedy doesn't end there. Valerie and her three sisters would clean their father's dust-covered overalls when he came back from the power stations, where he eventually became a site manager. 'He'd take his work clothes off in the conservatory and we'd beat them and get as much dust off as we could; otherwise our washing machine would get clogged up,' she recalls. Two of the four women have been diagnosed with plaques, as has one of their daughters.

In October, the Law Lords refused to overrule an appeal court ruling in January 2006 preventing plaques sufferers from claiming damages (in Rothwell v Chemical & Insulating Co). 'Proof of damage is an essential element in a claim in negligence and in my opinion the symptomless plaques are not compensatable,' ruled Lord Hoffmann.

That ruling will affect 'thousands who have faced emotional anguish since their diagnosis', says Adrian Budgen, head of the asbestos unit at law firm Irwin Mitchell. 'Plaques are a consequence of negligent exposure to asbestos. This exposure physically scars victims and is often a precursor to very serious and sometimes fatal disease.' Budgen, who is advising Valerie, adds: 'With a family history like theirs, you're going to be worried. She is a relatively young woman who has to live with this for the rest of her life.'

The Scottish government announced this month that it intended to reverse the Law Lords' ruling by introducing new legislation. 'The effects of asbestos are a terrible legacy of Scotland's industrial past and we should not turn our backs on those who contributed to our nation's wealth,' said Holyrood's Justice Secretary, Kenny MacAskill. 'Pleural plaques in anyone exposed to asbestos mean they have a greatly increased lifetime risk of developing mesothelioma. This will mean that people diagnosed with this condition will have to live with the worry of possible future ill-health for the rest of their lives.'

The Association of British Insurers calls the Scottish approach 'misguided'. Insurers are 'fully committed' to compensating claimants with mesothelioma and other asbestos-related diseases, says the ABI's Stephen Haddrill, but 'introducing legislation to overturn a unanimous Law Lords' ruling could significantly increase costs for Scottish businesses'.

None the less, insurers had been paying out for plaques for 20 years prior to the Rothwell case and payouts have been modest. Since the January 2006 ruling, 'full and final' damages, which settle the case once and for all, have been cut from £12,500-£20,000 to £5,000-£7,000.

There is a recent precedent for ministers in England and Wales stepping in to protect families from the courts when they overruled the House of Lords judgment by the Law Lords in the case of Sylvia Barker in 2006. In that case (The Observer, 5 March 2006), insurers argued that if there was more than one employer, compensation for mesothelioma should be split between them. As some have now gone out of business, this would have meant families missing out on part or all of their compensation. Ministers therefore amended the Compensation Act to protect families.

Campaigners are pessimistic about Westminster following the Scottish lead on plaques cases, even though the construction union Ucatt last week won a government commitment to review the Rothwell decision. 'It's going to look unjust if you have sufferers in Scotland receiving compensation and those south of the border aren't,' says Tony Whitson, chair of the Asbestos Victims Support Groups Forum UK.

Campaigners point to a growing difference between England and Wales on the one hand and Scotland on the other, where the life-extending drug Alimta is more readily available for mesothelioma sufferers and where bereavement payments of up to £30,000 have been made by the courts (such compensation is fixed at £10,000 in England). Now it seems likely plaques sufferers will only get compensation in Scotland.

Valerie says: 'What makes me angry is that if you have a minor scar on your body you can get compensation. Thousands of people receive compensation for stress, but we get nothing. The scarring is inside me.'

She says she suffers nightmares and has been out socialising only four times since she was diagnosed 18 months ago. 'Employers knew the harm asbestos was doing and carried on using it because it was cheap,' she says. 'Thousands of people are affected now and will be over the next 20 years and it all could have been prevented. It's so wrong.'

Source

Thursday, December 27, 2007

LegalView Blog Informs Readers of New Mesothelioma Cancer Treatment Center Being Built to Aid Mesothelioma Cancer Victims

LegalView.com offers readers several mesothelioma resources including its continually updated mesothelioma blog. A recent blog post regarding mesothelioma offered readers an inside into a new mesothelioma treatment center that is to be built in Australia.

Denver, CO (PRWEB) December 23, 2007 -- LegalView, the number one source for everything legal on the Internet, recently updated its mesothelioma legal blog to inform readers and sufferers of mesothelioma about a new mesothelioma treatment center that will be built. The new center is scheduled to be open in a year, but, according to news reports, the treatment center's first goal is to ensure that every mesothelioma cancer victim will be able to access treatments available at the center.

Mesothelioma is a deadly and rare form of cancer that is inevitably incurable at the moment. While research continues to lengthen a victim's life as well as to ease the pain the cancer causes, there is still no way to 100 percent treat the cancer. Mesothelioma is usually caused by exposure to asbestos fibers that are breathed into the lung and essentially crystallize causing the development of cancer cells on the lining of the lung. It is typical that mesothelioma occurs anywhere from 10 to 40 years after initial exposure to asbestos. Many are currently being diagnosed with the cancer because of years of negligence by companies who knowingly endangered employees by exposing them to the deadly dust. If you or anyone you know has developed mesothelioma cancer, it may be in your best interest to contact a mesotehlioma law firm for more information.

The new mesothelioma treatment center is being built in honor of a local Sydney man who recently passed away. Bernie Benton was exposed to asbestos and began helping others dealing with the same plight. The mesothelioma treatment center will be one of the world's first asbestos research centers that focuses only on mesothelioma. Those suffering from mesothelioma cancer can find more information on this and other mesothelioma treatments at the mesothelioma information portal.

In addition to information regarding mesothelioma, LegalView.com also offers resources on several additional legal issues that are tragically affecting individuals throughout the country everyday. Readers will be able to find a traumatic brain injury law firm who specializes in helping brain injury victims with consultations and attorney referral services. Individuals who have suffered from a construction accident injury or an auto accident can find information on finding a construction accident attorney or auto accident lawyer through LegalView as well.


SOURCE

Thursday, December 13, 2007

PLEURAL MESOTHELIOMA PROGNOSIS

The prognosis of mesothelioma refers to the possible outcome of mesothelioma. Malignant pleural mesothelioma is a lethal disease and little is known about prognostic factors. A few have survived as long as 5 years, with rates of 14% for all types and 46% for the epithelial type. However, there are long term pleural mesothelioma survivors who have survived more than 10 years (although very rare).

In a recent mesothelioma study, doctors writing about the prognosis of pleural mesothelioma explained that long-term mesothelioma survivors do exist and their prognosis may be independent of the treatment or therapies used.

Age, stage of disease, gender and histological subtype are factors that are considered when prognosis of pleural mesothelioma is being carried on. With trimodality treatment, some patients have survived 16-19 months. However, numbers are small. Despite a ban on asbestos (major cause) use in Western countries, the incidence of malignant pleural mesothelioma is increasing, due to the long delay between asbestos exposure and diagnosis.

Moreover, asbestos is still used in developing countries.Without treatment, mesothelioma is fatal within 4-8 months.

Mesothelioma news; Adelaide mum defies odds surviving mesothelioma

The World Today - Thursday, 13 December
ELEANOR HALL: The asbestos disease, mesothelioma, is usually a death sentence, killing its victims within a year But an Adelaide mother has defied the medical odds by not only surviving the deadly asbestos-related disease mesothelioma but having a child 10 years after her diagnosis।39-year-old Belinda Dunn took part in a gene therapy trial soon after she received the news she had mesothelioma।But medical experts are still baffled by her survival, as Nance Haxton reports from Adelaide.

NANCE HAXTON: Belinda Dunn is a medical mystery. Her only contact with deadly asbestos dust was as a small child when she played on a pile of fibro while her parents were extending their house. The 39-year-old Adelaide mother of one was diagnosed with mesothelioma soon after the birth of her first child, Nathan, 10 years ago, and told she had little chance of living beyond a year. But a decade on, not only has she survived the disease, but she is pregnant as well.

BELINDA DUNN: It's a very daunting thought, actually. Where I was 10 years ago to where I am now.

NANCE HAXTON: Belinda Dunn took part in an experimental gene therapy trial in the United States soon after her diagnosis. But she says she doesn't credit her current good health exclusively to that treatment.

BELINDA DUNN: I've taken lots and lots of vitamins at the time of - under the guidance of my naturopath - with the gene therapy trial, and I'm just wondering if it was because my immune system was in good shape when I had the trial that perhaps that's helped it

NANCE HAXTON: And you've had no complications with the pregnancy from the mesothelioma so far?

BELINDA DUNN: Well, not from - not anything I've had normally for the last 10 years, because I suffer, still, like an arthritic type pain, like shoulder tip pain and I know when my mesothelioma is active, if you want to call it that, or it's my chest is inflamed and basically, I just live with that. And that's part of being pregnant and having mesothelioma.

NANCE HAXTON: Professor Doug Henderson from the Flinders Medical Centre in Adelaide was the doctor who initially diagnosed Belinda Dunn with mesothelioma. He says he never would have thought 10 years on from that day that he would be talking about her still being alive and well.

DOUG HENDERSON: I certainly didn't - it's a very unexpected but very positive and good outcome

NANCE HAXTON: But Professor Henderson says sadly, Belinda Dunn's recovery cannot be explained by science, and therefore has little significance at this stage for other sufferers.

DOUG HENDERSON: I have seen other rare cases of mesothelioma that have gone into apparently spontaneous complete remission and one patient whom I remember very vividly was alive with a completely normal chest X-ray and otherwise well, eight years after the diagnosis had been made.

NANCE HAXTON: What can this be put down to?

DOUG HENDERSON: We don't know the reasons for spontaneous regression like this in tumors. It might be due to some altered cellular dynamics within the tumor itself, but why that should happen we really have no clear idea. The other theory is that the immune system of a body somehow gains a boost and gains ascendancy over the tumor and puts it into remission.

NANCE HAXTON: So are there any ramifications from these rare cases that could be applied to other victims of this disease?

DOUG HENDERSON: I don't think so, these are the exceptions rather than the rule and I'm not sure that one could use these people or any factor from these people to treat other patients, because we don't know what the factors that are involved in this type of remission really are. I think only time will tell the eventual outcome but I hope that Belinda will have a virtually normal life expectancy, taking into account that she's now been in apparently complete remission with no evidence of progressive disease for some 10 years.


NANCE HAXTON: While Ms Dunn is grateful for her health, she struggles with losing many of the friends she has made through asbestos disease support groups, including Bernie Banton. She hopes that her case, while something of a miracle, gives hope to other people with mesothelioma - which it does not have to be a death sentence.

BELINDA DUNN: I really hope, you know, that that's what it's doing because, you know, if it's worked for me, surely someone will start thinking about what I had been doing with the vitamins when I had my trial and perhaps they can move on to do some research into what I was taking when I had the gene therapy, and perhaps someone else might be lucky and live with mesothelioma.
That's the mystery mesothelioma survivor, Belinda Dunn.

Wednesday, December 12, 2007

PLEURAL MESOTHELIOMA DIAGNOSIS

Presently there seems to be no cure for mesothelioma, but its early diagnosis can provide doctors the opportunity to relieve the patients of a great deal of suffering, and prolong their lives thus improving their general health outlook। These treatment options depend on the stage and the overall progession of the disease. The pleural form of mesothelioma, which represents more than 90% of all cases, presents on x-ray as diffuse unilateral or bilateral pleural thickening that appears to encase the lungs, usually producing blunting of the costophrenic angles. Pleural effusions are present in 95% of cases and are typically unilateral, massive effusions.





Diagnosis is majorly based on pleural fluid cytology or open pleural biopsy and, if these are nondiagnostic, biopsy by video-assisted thorascopic surgery (VATS) or thoracotomy is used.
Staging is done with chest CT, mediastinoscopy, and MRI. Sensitivity and specificity of MRI and CT are comparable, although MRI is helpful in determining tumor extension into the spine or spinal cord. PET may have better sensitivity and specificity for distinguishing benign from malignant pleural thickening.
Using Bronchoscopy rules out coexisting endobronchial malignancies। Increased hyaluronidase levels in pleural fluid are suggestive but not diagnostic of disease. Soluble mesothelin-related proteins released into the serum by mesothelial cells are being studied as possible tumor markers for disease detection and monitoring.


Mesothelioma स्टील remains an incurable cancer.

Tuesday, December 11, 2007

MESOTHELIOMA NEWS; Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed

In our quest to finding a lasting solution to mesothelioma, hope seems not to be lost.

Earlier this year Rosetta Genomics, Ltd. announced that it had partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung and mesothelioma cancers.
The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking, as well as those who have been exposed to asbestos fibers. The test will utilize Rosetta Genomics' proprietary protocol to extract microRNAs from a simple blood draw.

"A test that will be able to detect cancer at an early stage using a simple blood draw will have far reaching implications on the fight against cancer," noted Dr. Harvey Pass, Professor and Chief, Division of Thoracic Surgery and Thoracic Oncology at NYU Medical Center.

"MicroRNAs have been shown to hold great potential as effective biomarkers for various cancers, and I believe that NYU Medical Center's vast experience with lung cancer and Mesothelioma, coupled with Rosetta Genomics' expertise in the microRNA field, will allow us to successfully advance this much needed test forward."

This new development will help in future diagnoses and for lasting treatment for the rare deadly disease. Other firms are also developing new treatment options, but for now, I think one has to avoid asbestos as possible as one can, to prevent contacting this disease.

Monday, December 10, 2007

SYMPTOMS OF PLEURAL MESOTHELIOMA

Pleural mesothelioma is a disease whose symptoms are not easily noticeable. Although at the early stages of the disease patients do complain of recurring heart and chest pains.



Generally the symptoms are always mild at the initial stages but do get serious and complicated as soon as it reaches its matured that is when it becomes visible. Chest pain is the most common. Other symptoms include; coughs, weight loss and anorexia. Others are persistent coughing, difficulty in swallowing, facial swelling, weight loss, fever, rasping, and coughing up blood.



In some cases patients do complain of shortness of breath. This is as a result of the thickening of the pleura as the tumour begins to spread. This makes it to be filled with fluid. This fluid leads to the discomfort or pain associated with first detection of the disease.



Pleural mesothelioma patients display all three types of mesothelioma cancer cells: epithelioid mesothelioma, sarcomatoid mesothelioma and biphasic mesothelioma

PLEURAL MESOTHELIOMA

When the famous Australian anti-racism activist Bob Bellear died in 2005 of mesothelioma, not until then did the disease started becoming popular. Mesothelioma occurs in different forms of which pleural mesothelioma is one.

Pleura mesothelioma is a form of mesothelioma that occurs around the lungs and respiratory area of the chest region. It attacks the cell and the linings of the lungs which are known as the pleura, hence the name pleura.





It do start from the lungs and in some cases spread to other parts of the body including the brain thereby causing more damage than not





Sometimes it occur in two forms- benign (non-cancerous) and malignant (cancerous) but malignant is the most common of the two.
It is the most common form of mestheolima, 7-8 out of every 10 cases of mesothelioma cases are mesothelioma of the pleura. Due to the nature of this disease it might take 30-50years before the symptoms start to surface after being exposed to asbestos. This makes the disease not to be known until when it is too late.

Saturday, December 8, 2007

MESOTHELIOMA DIAGNOSIS

The diagnosis of mesothelioma is not always an easy task for doctors and researchers. This is due to the numerous symptoms of mesothelioma which are evidences of the presence of other diseases and the latency between the period of contraption and showing of symptoms.

Hence it is always important to check the medical file of a patient when diagnosing. In most cases mesothelioma is usually in its matured stage which makes it a little bit hard for much to be known. A diagnosis of mesothelioma is obtained firstly, through the assessment of the patient’s medical file, a CT scan (computerized technology) or CAT (computerized axial tomography), MRI (magnetic resonance imaging) and a biopsy. The CT helps to take internal pictures of the internal organs of the body while the MRI allows getting perfect detailed images of the inner body are through a powerful magnet linked to computer.

The scans are followed by a biopsy which is used to confirm the presence of mesothelioma. To perform biopsy, a close examination is made on the fluids surrounding the lungs, when present, by an oncologist. This might not be sufficient, so, a small cut might be made to remove a tissue from the patient with a hollow needle which is inserted into the patient's chest cavity to run biopsy on. This process is known as thorascopy. This is altogether known as open pleural biopsy. The process is known as peritoneoscopy if the tissues are taken from the abdominal cavity.

The disease is declared localized if the cancer is found on the surface of the membrane, but it will be advanced if it has spread to other parts of the body. The early detection of mesothelioma depends on the patients’ awareness of its presence. Diagnosis of mesothelioma is always poor due to the fact that it is rare, the non-specific nature of its symptoms, and the time lag between asbestos exposure and a patient’s symptomatic response, could take 50 years. Despite all this frictions, there are many available procedures or the diagnoses of mesothelioma.


MESOTHELIOMA PROGNOSIS

The prognosis of mesothelioma refers to the possible outcome of mesothelioma. Mesothelioma prognosis and treatment options is determined by the size of of the tumour, the stage of the tumour, the duration of the mesothelioma tumour, the type of the mesothelioma tumour, the overall health and age of the patient, the level of exposure to asbestos and whether cancerous cells could be located in other parts of the body. Chances of recovery, recovery period for mesotholima, the survival rate of mesothelioma, the death rate and all possible outcomes are also entailed in the prognosis of mesothelioma.


Diagnosis is then conducted through physical examination and results which confirms a full mesthelioma prognosis. After this, treatments options are now considered to determine the best treatment option.
Due to the incurability of mesothelioma treatment options are designed to relieve symptoms, prevent metastasis and prolong life expectancy. Diagnosis plays a vital role in mesothelioma prognosis. The earlier the diagnosis, the earlier the better as it becomes worse the longer the cancer is left unknown as there might be no curative treatment. But in most cases, mesothelioma is usually diagnosed in its matured stage, this makes mesothelioma to be a little bit hard to understand, thus the seven percent in five years survival rate. Yet, sufferers do have a reason to hope.


Scientists are already developing new methods and the FDA now allows the pharmaceutical industry to try new compounds o mesothelioma patients which may make the survival rate to be high next year. It is advisable for one when he/she is diagnosed of mesothelioma to contact a doctor for proper care and help.


Thursday, December 6, 2007

TYPES OR FORMS OF MESOTHELIOMA CANCER

The type of mesothelioma is determined on the basis where the cancer occurs in the body. Mesothelioma may affect any part or organ of the body depending on the level of exposure to asbestos and the time level over which the patient has been exposed to.
The major types of mesthelioma cancer includes the following;

* Pleural Mesothelioma

*Peritoneal Mesothelioma

* Pericardial Mesothelioma

Pleural Mesothelioma

Pleural mesothelioma, also known as mesothelioma of the pleura is a tumour in which the lining of the lungs, or lung pleura, gets affected by malignant cells. It is one of the most commonly occurring cancers. The pleura is a thin tissue around the lungs and the inside of the chest.
It helps the lungs in breathing (respiration) by producing a serous fluid that lubricates the pleural surfaces to avoid the teasing of the lungs against the chest wall. In order to protect the lungs, the pleura produces a small amount of fluid which helps cushion the lungs, making the lungs move more smoothly during breathing.

Types of pleural mesothelioma cancer

Diffused or Malignant (Cancerous) MESOTHELIOMA

Malignant Pleural mesothelioma is cancerous and can spread to other parts of the body. This rare form of cancer is found in the pleural sac lining of the lung. Exposure to asbestos is considered the primary cause of pleural mesothelioma.

Benign (Non-Cancerous) pleural mesothelioma

This is the non-cancerous form of pleural mesothelioma, which does not affect all parts of the body but the pleura. However, it constricts the lung causing shortness of breath, and in some severe cases, pneumothorax (lung failure)

Peritoneal mesothelioma

This is the next common type of mesothelioma which affects peritonium which is the lining of the abdominal cavity including the stomach. It is more aggressive than the mesothelioma of the pleura. Its symptoms include the following chest pain, anaemia, breathlessness, loss of appetite and other severe symptoms. It could either be malignant (cancerous) or benign (non-cancerous). Their is a high probability of women being diagnosed with peritoneal mesothelioma than other types of mesothelioma.

Pericardial mesothelioma

This is the rarest and least but deadliest type of mesothelioma because it affects the heart and the cavity surrounding it. It is said to have an average lifespan of less than six months from diagnosis. Due to the rarity of this disease as many patients are ignorant of the presence of this disease in their body until diagnosis is made on their autopsies, it makes it difficult for doctors and researchers to understand the whole logic behind the nature of this disease.

Symptoms might include congestive heart failure, palpitation, night sweat, persistent cough, chest pain and breathing disorder. Pericardial mesothelioma can sometimes be palpatively treated through surgery and further treatment of radiation and chemotherapy.

Every year about 2,000 new cases of mesothelioma are being diagnosed, and the figure might still be increasing. The major cause of mesothelioma has been linked to asbestos inhaling due to being exposed to it. So watch out next time you are out in mining area.

Wednesday, December 5, 2007

Other treaments for malignant mesothelioma

There are other different types of treatment for patients with malignant mesothelioma.


Different types of treatments are available for patients with malignant mesothelioma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. Before starting treatment, patients may want to think about taking part in a clinical trial. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment.


Clinical trials are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI Web site. Choosing the most appropriate cancer treatment is a decision that ideally involves the patient, family, and health care team.
Three types of standard treatment are used:

Surgery


The following surgical treatments may be used for malignant mesothelioma:


Wide local excision: Surgery to remove the cancer and some of the healthy tissue around it.


Pleurectomy and decortication: Surgery to remove part of the covering of the lungs and lining of the chest and part of the outside surface of the lungs.


Extrapleural pneumonectomy: Surgery to remove one whole lung and part of the lining of the chest, the diaphragm, and the lining of the sac around the heart.


Pleurodesis: A surgical procedure that uses chemicals or drugs to make a scar in the space between the layers of the pleura. Fluid is first drained from the space using a catheter or chest tube and the chemical or drug is put into the space. The scarring stops the build-up of fluid in the pleural cavity. Even if the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after surgery, to increase the chances of a cure, is called adjuvant therapy.

Radiation therapy


Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells. There are two types of radiation therapy. External radiation therapy uses a machine outside the body to send radiation toward the cancer. Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. The way the radiation therapy is given depends on the type and stage of the cancer being treated.

Chemotherapy


Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping the cells from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the spinal column, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is the use of more than one anticancer drug. The way the chemotherapy is given depends on the type and stage of the cancer being treated.


New types of treatment that are being tested in clinical trials include the following:

Biologic therapy


Biologic therapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. This type of cancer treatment is also called biotherapy or immunotherapy.

Saturday, December 1, 2007

TREATMENTS FOR MALIGNANT MESOTHELIOMA



TREATMENTS OF MALIGNANT MESOTHELIOMA

Physical exam and history
: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient’s health habits, exposure to asbestos, past illnesses and treatments will also be taken.
Chest x-ray: An x-ray of the organs and bones inside the chest. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.
Complete blood count (CBC): A procedure in which a sample of blood is drawn and checked for the following:
The number of red blood cells, white blood cells, and platelets.
The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.
The portion of the blood sample made up of red blood cells.
Sedimentation rate: A procedure in which a sample of blood is drawn and checked for the rate at which the red blood cells settle to the bottom of the test tube.
Biopsy: The removal of cells or tissues from the pleura or peritoneum so they can be viewed under a microscope by a pathologist to check for signs of cancer. Procedures used to collect the cells or tissues include the following:
Fine-needle aspiration biopsy: The removal of part of a lump, suspicious tissue, or fluid, using a thin needle. This procedure is also called a needle biopsy.
Lung biopsy. The patient lies on a table that slides through the computed tomography (CT) machine which takes x-ray pictures of the inside of the body. The x-ray pictures help the doctor see where the abnormal tissue is in the lung. A biopsy needle is inserted through the chest wall and into the area of abnormal lung tissue. A small piece of tissue is removed through the needle and checked under the microscope for signs of cancer.

Thoracoscopy: An incision (cut) is made between two ribs and a thoracoscope (a thin, lighted tube) is inserted into the chest.
Peritoneoscopy: An incision (cut) is made in the abdominal wall and a peritoneoscope (a thin, lighted tube) is inserted into the abdomen.
Laparotomy: An incision (cut) is made in the wall of the abdomen to check the inside of the abdomen for signs of disease.
Thoracotomy: An incision (cut) is made between two ribs to check inside the chest for signs of disease.
Bronchoscopy: A procedure to look inside the trachea and large airways in the lung for abnormal areas. A bronchoscope (a thin, lighted tube) is inserted through the nose or mouth into the trachea and lungs. Tissue samples may be taken for biopsy.
Bronchoscopy. A bronchoscope is inserted through the mouth, trachea, and major bronchi into the lung, to look for abnormal areas. A bronchoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a cutting tool. Tissue samples may be taken to be checked under a microscope for signs of disease.
Cytologic exam: An exam of cells under a microscope (by a pathologist) to check for anything abnormal. For mesothelioma, fluid is taken from around the lungs or from the abdomen. A pathologist checks the cells in the fluid.
Certain factors affect prognosis (chance of recovery) and treatment options.
The prognosis (chance of recovery) and treatment options depend on the following:
The stage of the cancer.

The size of the tumor.

Whether the tumor can be removed completely by surgery.

The amount of fluid in the chest or abdomen.

The patient's age and general health, including lung and heart health.

The type of mesothelioma cancer cells and how they look under a microscope.
Whether the cancer has just been diagnosed or has recurred (come back).

Stages of Malignant Mesothelioma

After malignant mesothelioma has been diagnosed, tests are done to find out if cancer cells have spread to other parts of the body. The stages of malignant mesothelioma are divided into two groups.

Localized malignant mesothelioma (stage I) Advanced malignant mesothelioma (stage II, stage III, and stage IV)

After malignant mesothelioma has been diagnosed, tests are done to find out if cancer cells have spread to other parts of the body. The process used to find out if cancer has spread outside the pleura or peritoneum is called staging. The information gathered from the staging process determines the stage of the disease. It is important to know the spread of the cancer in order to plan treatment.

The following tests and procedures may be used in the staging process:


Chest x-ray: An x-ray of the organs and bones inside the chest. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.

CT scan (CAT scan): A procedure that makes a series of detailed pictures of the chest and abdomen, taken from different angles. The pictures are made by a computer linked to an x-ray machine. A dye may be injected into a vein or swallowed to help the organs or tissues show up more clearly. This procedure is also called computed tomography, computerized tomography, or computerized axial tomography.

MRI (magnetic resonance imaging): A procedure that uses a magnet, radio waves, and a computer to make a series of detailed pictures of the chest or abdomen. This procedure is also called nuclear magnetic resonance imaging (NMRI). The stages of malignant mesothelioma are divided into two groups.

Malignant mesothelioma stages are grouped into localized and advanced.

Localized malignant mesothelioma (stage I)

In localized malignant mesothelioma, cancer is found in the lining of the chest wall and may also be found in the lining of the lung, the lining of the diaphragm, or the lining of the sac that covers the heart on the same side of the chest.

Advanced malignant mesothelioma (stage II, stage III, and stage IV)

Advanced malignant mesothelioma includes stage II, stage III, and stage IV.

In stage II, cancer is found in the lining of the chest wall and the lymph nodes on the same side of the chest. Cancer may also be found in the lining of the lung, the lining of the diaphragm, or the lining of the sac that covers the heart on the same side of the chest.

In stage III, cancer has spread to any of the following areas: The chest wall. The mediastinum. The heart. Beyond the diaphragm. The peritoneum.

Cancer may have also spread to lymph nodes on the other side of the chest or outside the chest. In stage IV, cancer has spread to distant organs or tissues.

Recurrent Malignant Mesothelioma

Recurrent malignant mesothelioma is cancer that has recurred (come back) after it has been treated. The cancer may come back in the chest or abdomen or in other parts of the body.

Friday, November 30, 2007

MALIGNANT MESOTHELIOMA

Malignant mesothelioma is a disease in which malignant (cancer) cells form in the lining of the chest or abdomen. Malignant mesothelioma is a disease in which malignant (cancer) cells are found in the pleura (the thin layer of tissue that lines the chest cavity and covers the lungs) or the peritoneum (the thin layer of tissue that lines the abdomen and covers most of the organs in the abdomen). This summary is about malignant mesothelioma of the pleura.


Anatomy of the respiratory system, showing the trachea and both lungs and their lobes and airways. Lymph nodes and the diaphragm are also shown. Oxygen is inhaled into the lungs and passes through the thin membranes of the alveoli and into the bloodstream


Being exposed to asbestos can affect the risk of developing malignant mesothelioma.
Many people with malignant mesothelioma have worked or lived in places where they inhaled or swallowed asbestos. After being exposed to asbestos, it usually takes a long time for malignant mesothelioma to occur. Other risk factors for malignant mesothelioma include the following:
Living with a person who works near asbestos. Being exposed to a certain virus. Possible signs of malignant mesothelioma include shortness of breath and pain under the rib cage.

Sometimes the cancer causes fluid to collect around the lung or in the abdomen. These symptoms may be caused by the fluid or malignant mesothelioma. Other conditions may cause the same symptoms. A doctor should be consulted if any of the following problems occur:

Trouble breathing.
Pain under the rib cage.
Pain or swelling in the abdomen.
Lumps in the abdomen.
Weight loss for no known reason.

Tests that examine the inside of the chest and abdomen are used to detect (find) and diagnose malignant mesothelioma.
Sometimes it is hard to tell the difference between malignant mesothelioma and lung cancer. The following tests and procedures may be used:



Test for malignant mesthelioma


Physical exam and history: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual. A history of the patient’s health habits, exposure to asbestos, past illnesses and treatments will also be taken.

Chest x-ray: An x-ray of the organs and bones inside the chest. An x-ray is a type of energy beam that can go through the body and onto film, making a picture of areas inside the body.
X-rays are used to take pictures of organs and bones of the chest.X-rays pass through the patient onto film.


Complete blood count (CBC): A procedure in which a sample of blood is drawn and checked for the following:The number of red blood cells, white blood cells, and platelets.The amount of hemoglobin (the protein that carries oxygen) in the red blood cells.The portion of the blood sample made up of red blood cells.Sedimentation rate: A procedure in which a sample of blood is drawn and checked for the rate at which the red blood cells settle to the bottom of the test tube.


Biopsy: The removal of cells or tissues from the pleura or peritoneum so they can be viewed under a microscope by a pathologist to check for signs of cancer. Procedures used to collect the cells or tissues include the following:Fine-needle aspiration biopsy: The removal of part of a lump, suspicious tissue, or fluid, using a thin needle. This procedure is also called a needle biopsy.



The patient lies on a table that slides through the computed tomography (CT) machine which takes x-ray pictures of the inside of the body. The x-ray pictures help the doctor see where the abnormal tissue is in the lung. A biopsy needle is inserted through the chest wall and into the area of abnormal lung tissue. A small piece of tissue is removed through the needle and checked under the microscope for signs of cancer.


Thoracoscopy: An incision (cut) is made between two ribs and a thoracoscope (a thin, lighted tube) is inserted into the chest.


Peritoneoscopy: An incision (cut) is made in the abdominal wall and a peritoneoscope (a thin, lighted tube) is inserted into the abdomen.


Laparotomy: An incision (cut) is made in the wall of the abdomen to check the inside of the abdomen for signs of disease.


Thoracotomy: An incision (cut) is made between two ribs to check inside the chest for signs of disease.


Bronchoscopy: A procedure to look inside the trachea and large airways in the lung for abnormal areas. A bronchoscope (a thin, lighted tube) is inserted through the nose or mouth into the trachea and lungs. Tissue samples may be taken for biopsy.


A bronchoscope is inserted through the mouth, trachea, and major bronchi into the lung, to look for abnormal areas. A bronchoscope is a thin, tube-like instrument with a light and a lens for viewing. It may also have a cutting tool. Tissue samples may be taken to be checked under a microscope for signs of disease.


Cytologic exam: An exam of cells under a microscope (by a pathologist) to check for anything abnormal. For mesothelioma, fluid is taken from around the lungs or from the abdomen. A pathologist checks the cells in the fluid. Certain factors affect prognosis (chance of recovery and treatment options.
The prognosis (chance of recovery) and treatment options depend on the following:

The stage of the cancer.
The size of the tumor.
Whether the tumor can be removed completely by surgery.
The amount of fluid in the chest or abdomen.
The patient's age and general health, including lung and heart health.
The type of mesothelioma cancer cells and how they look under a microscope. Whether the cancer has just been diagnosed or has recurred (come back).

What is MESOTHELIOMA ASBESTOS?

''mesotheolima asbestos'' is the generic name of a cancer disease called mesotheolima. Mesotheolima [otherwise spelt as mesothelioma] is a disease in which cells of the mesothelium become malignant and abnormal. Mesotheolium is a sac-like membrane or lining that covers and protects most of the internal organs of the body. The mesothelium produces a lubricating fluid that is released between these layers, allowing moving organs (such as the beating heart and the expanding and contracting lungs) to glide easily against adjacent structures. It is from this that the disease get its name,the definition of the word mesothelioma is literally ''cancer of the mesothelium'' (-oma being a medical term for cancer).The mesothelium has different names, depending on its location in the body. -The peritoneum is the mesothelial tissue that covers most of the organs in the abdominal cavity. -The pleura is the membrane that surrounds the lungs and lines the wall of the chest cavity. -The pericardium covers and protects the heart. -The tunica vaginalis testis is the mesothelial tissue surrounding the male internal reproductive organs. -The tunica serosa uteri covers the internal reproductive organs in women. The generic name "asbestos" belongs to a group of minerals called "asbestiform" minerals. Asbestos is a fibrous material which is mined from serpentine rock. Basically, rock is mined and crushed. When the rock is crushed, fibrous stands of asbestos are extracted from the rock. The strands are put in bags and shipped to manufacturing facilities where the asbestos are used as materials in insulation and other materials. The three most commonly used forms of asbestos in product manufacturing are chrysotile, amosite and crocidolite. If tiny asbestos particles float in the air, especially during the manufacturing process, they may be inhaled or swallowed, and can cause serious health problems. In addition to mesothelioma, exposure to asbestos increases the risk of lung cancer, asbestosis (a noncancerous, chronic lung ailment), and other cancers, such as those of the larynx and kidney.Working with asbestos is the major risk factor for mesothelioma. A history of asbestos exposure at work is reported in about 70 percent to 80 percent of all cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos.The risk of asbestos-related disease increases with heavier exposure to asbestos and longer exposure time. However, some individuals with only brief exposures have developed mesothelioma. On the other hand, not all workers who are heavily exposed develop asbestos-related diseases. Smoking does not appear to increase the risk of mesothelioma. However, the combination of smoking and asbestos exposure significantly increases a person’s risk of developing cancer of the air passageways in the lung. Mesothelioma is so difficult to diagnose early because the symptoms are often mistaken for those of other, less serious ailments. To make matters worse, it often takes many years for the symptoms to show up after the asbestos exposure has taken place. It might take 30-50 years.Here is a list of the most common Mesothelioma symptoms:* Difficulty breathing (shortness of breath) * Persistent cough* Change in your normal coughing pattern* Coarse or raspy voice* Unexplainable weight loss* Difficulty in swallowing* Chest or abdominal pain* Coughing up blood * Bowel obstruction* Blood clotting abnormalities* Anaemia* FeverWhen one has mesotheolima and your doctor is unaware that you have been exposed to asbestos, he or she is unlikely to assume that you may have mesothelioma and will instead test for a number of other more common diseases that are associated with your symptoms. People who have worked with asbestos or who have close contact with someone that works with asbestos should therefore always be vigilant in looking out for any of these symptoms and seeking medical advice if any or all of the symptoms manifest. They should also make their doctor aware that they have worked with asbestos so that no further time is wasted in testing for other types of disease. Much of the delay in diagnosing mesothelioma comes from lack of information and awareness on both the part of the doctor and the patient.However, it is up to the patient, who is aware of the asbestos exposure, to increase the chances of a speedy diagnosis by making the doctor aware of the circumstances and keeping an eye out of any tell tale signs that mesothelioma may be present.

What is MESOTHEOLIMA ASBESTOS?

''mesotheolima asbestos'' is the generic name of a cancer disease called mesotheolima. Mesotheolima [otherwise spelt as mesothelioma] is a disease in which cells of the mesothelium become malignant and abnormal. Mesotheolium is a sac-like membrane or lining that covers and protects most of the internal organs of the body. The mesothelium produces a lubricating fluid that is released between these layers, allowing moving organs (such as the beating heart and the expanding and contracting lungs) to glide easily against adjacent structures.

It is from this that the disease get its name,the definition of the word mesothelioma is literally ''cancer of the mesothelium'' (-oma being a medical term for cancer).The mesothelium has different names, depending on its location in the body.
-The peritoneum is the mesothelial tissue that covers most of the organs in the abdominal cavity.
-The pleura is the membrane that surrounds the lungs and lines the wall of the chest cavity.
-The pericardium covers and protects the heart.
-The tunica vaginalis testis is the mesothelial tissue surrounding the male internal reproductive organs.
-The tunica serosa uteri covers the internal reproductive organs in women.

The generic name "asbestos" belongs to a group of minerals called "asbestiform" minerals. Asbestos is a fibrous material which is mined from serpentine rock. Basically, rock is mined and crushed. When the rock is crushed, fibrous stands of asbestos are extracted from the rock. The strands are put in bags and shipped to manufacturing facilities where the asbestos are used as materials in insulation and other materials. The three most commonly used forms of asbestos in product manufacturing are chrysotile, amosite and crocidolite. If tiny asbestos particles float in the air, especially during the manufacturing process, they may be inhaled or swallowed, and can cause serious health problems.

In addition to mesothelioma, exposure to asbestos increases the risk of lung cancer, asbestosis (a noncancerous, chronic lung ailment), and other cancers, such as those of the larynx and kidney.Working with asbestos is the major risk factor for mesothelioma. A history of asbestos exposure at work is reported in about 70 percent to 80 percent of all cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos.The risk of asbestos-related disease increases with heavier exposure to asbestos and longer exposure time. However, some individuals with only brief exposures have developed mesothelioma. On the other hand, not all workers who are heavily exposed develop asbestos-related diseases. Smoking does not appear to increase the risk of mesothelioma.

However, the combination of smoking and asbestos exposure significantly increases a person’s risk of developing cancer of the air passageways in the lung. Mesothelioma is so difficult to diagnose early because the symptoms are often mistaken for those of other, less serious ailments.

To make matters worse, it often takes many years for the symptoms to show up after the asbestos exposure has taken place. It might take 30-50 years.
Here is a list of the most common Mesothelioma symptoms:

* Difficulty breathing (shortness of breath)
* Persistent cough
*Change in your normal coughing pattern
* Coarse or raspy voice
* Unexplainable weight loss
* Difficulty in swallowing
* Chest or abdominal pain
* Coughing up blood
* Bowel obstruction
* Blood clotting abnormalities
* Anaemia
* Fever

When one has mesotheolima and your doctor is unaware that you have been exposed to asbestos, he or she is unlikely to assume that you may have mesothelioma and will instead test for a number of other more common diseases that are associated with your symptoms. People who have worked with asbestos or who have close contact with someone that works with asbestos should therefore always be vigilant in looking out for any of these symptoms and seeking medical advice if any or all of the symptoms manifest.

They should also make their doctor aware that they have worked with asbestos so that no further time is wasted in testing for other types of disease. Much of the delay in diagnosing mesothelioma comes from lack of information and awareness on both the part of the doctor and the patient.However, it is up to the patient, who is aware of the asbestos exposure, to increase the chances of a speedy diagnosis by making the doctor aware of the circumstances and keeping an eye out of any tell tale signs that mesothelioma may be present.

Monday, November 12, 2007

Anxiety over Amaca asbestos case

Elizabeth Gosch and Ean Higgins

October 24, 2007 05:58am

LAWYERS for asbestos victims fear the new board of the James Hardie subsidiary Amaca is using a WA case to attempt to limit the number of successful lawsuits.

Denis Walter John Moss and his wife, Patricia Margaret Hannell, won a case against Amaca Pty Ltd, the James Hardie asbestos-producing subsidiary, in December last year and were awarded $5million.

Mr Moss, who died in June, was exposed to asbestos in the mid-1980s and 1990 as a result of occasional work on asbestos cement products in and around his home. He was diagnosed with mesothelioma in November 2005.

Amaca appealed against the West Australian Supreme Court decision earlier this year to award damages. The Court of Appeal overturned the trial judge's decision, stating Amaca did not breach its duty of care by failing to advertise the dangers of asbestos in the mass media.

Today in Perth, Mrs Hannell is seeking special leave to appeal against that decision in the High Court.

For decades, the key tenet of asbestos disease litigation, particularly in New South Wales, has been the finding by the courts that James Hardie had actual knowledge of the dangers of asbestos as early as 1938 but did not do enough toprotect workers and warn customers.

Slater and Gordon asbestos litigation specialist Tanya Segelov said it was possible the new Amaca board - appointed by James Hardie and the NSW Government - was testing the water in Western Australia, and if successful, might take a harder line in other jurisdictions.

If Amaca won such cases, it could reduce the ability of thousands of future victims to obtain compensation.

SOURCE

Union Efforts Called Racketeering

A lawsuit filed by Smithfield Foods charges the UFCW with extortion and a smear campaign in the union's efforts to convince the meat processor to agree to voluntarily accept the union without an employee vote. The union says the company has a long history of worker intimidation.

By Joseph A. Slobodzian

It's been used against mobsters, corrupt labor unions and anti-abortion protesters.

Now Smithfield Foods Inc., the Virginia-based meat-processing giant, has joined companies turning to federal racketeering law to try to block a campaign geared to unionization of its employees.

Smithfield Foods' lawyers filed the civil racketeering lawsuit Oct. 17 in federal court in Richmond, Va., the latest development in Smithfield's 14-year fight to prevent the United Food and Commercial Workers from unionizing 4,650 hourly workers at its largest pork-processing plant in Tar Heel, N.C.

The lawsuit contends that the union has resorted to "smear tactics," including trying to undermine the company's stock price by leaking false statements to Wall Street stock analysts.

The lawsuit seeks damages of at least $5.9 million for business losses Smithfield Foods says can be traced to the union campaign, as well as an injunction barring the unions from continuing their activities.

The lawsuit -- Smithfield Food Inc. vs. United Food and Commercial Workers International Union -- has been assigned to U.S. District Judge Robert E. Payne.

UFCW officials issued a statement maintaining that Smithfield has a long history of worker intimidation and calling the lawsuit an attempt by Smithfield to avoid a union vote.

UFCW officials noted that the suit was filed two days after negotiators for the company walked out of talks that were close to setting a mutually agreed-upon process for holding a unionization election at the Tar Heel processing plant.

"It is truly shameful that Smithfield is willing to spend millions of dollars on high-priced lawyers and frivolous lawsuits rather than committing the resources needed to provide basic safety and health improvements for Tar Heel workers," the union statement read.

According to the lawsuit, union members have demonstrated at food stores carrying Smithfield Foods products and at public appearances of celebrity chef Paula Deen to urge her to break her contract with Smithfield. Deen's Food Network cable television program, Paula's Home Cooking, features Smithfield products.

The lawsuit contends that in September 2005, the UFCW's Local 400 "decided to abandon all efforts to convince Smithfield employees of the benefits of union membership in favor of a new plan aimed not at the employees, but at Smithfield itself."

The lawsuit says UFCW decided to "extort" Smithfield's recognition of Local 400 "regardless of the degree of actual employee support for such representation, by injuring Smithfield economically until Smithfield either agreed to [union] demands or was run out of business."

In addition to the UFCW international union, in Washington, and Local 400, the Smithfield lawsuit names three groups and seven individuals it describes as "co-conspirators" with the union.

While the use of the federal racketeering statute in a union-organizing dispute may seem unusual, other companies have turned to the racketeering law, says Lynn C. Outwater, a labor relations lawyer and managing partner of the Pittsburgh office of the law firm Jackson Lewis.

Outwater cited the March ruling by U.S. District Judge Brian M. Cogan, of the Eastern District of New York, allowing a civil-racketeering conspiracy case to proceed against the Laborers' International Union.

The lawsuit by the Asbestos & Lead Removal Corp. contended that Laborers Local 78 and business manager Edison Severino carried out a campaign of violence and extortion designed to force the company to agree to a collective-bargaining agreement with Local 78.

The stakes are high in the protracted unionization struggle between Smithfield and the UFCW. With annual sales of $12 billion, Smithfield Foods calls itself the largest producer of hogs and the "leading processor and marketer of fresh pork and processed meats in the United States."

The Tar Heel plant is the largest meat processing plant of its type, according to Smithfield Farms, and slaughters, processes and packages more than 32,000 hogs per day.

The UFCW, on the other hand, represents 1.4 million workers and Landover, Md.-based Local 400 claims 40,000 members.

Local 400 began trying to organize Smithfield's Tar Heel workers in 1994, two years after the sprawling processing plant opened.

SOURCE

Asbestos Exposure only Known Link to Pleural Mesothelioma

Los Angeles, CA: Even though asbestos has been a dirty word for decades, and its use and prevalence has dramatically declined, the toxic substance is still making its presence felt, and is still at the root cause of serious health problems including pleural mesothelioma. In many cases it is claiming lives.

Walter Kot of Illinois is just the latest worker to file a lawsuit against a host of corporations he claims were negligent in their responsibility to inform workers about the presence of asbestos and ways in which, through hygiene and other practises, to mitigate its spread and prevalence.

Kot is upset that on numerous occasions he transported, unknowingly, asbestos fibres home.
Kot toiled as a labourer, sheet-metal worker, shipper, forester and firefighter at the behest of a number of companies from 1940 through 1980. This past July he was diagnosed with mesothelioma, and is litigating a total of 49 corporations for damages and compensation, which will ultimately help cover his medical bills.

In his lawsuit, filed last week in Madison County, Kot claims that the defendants should have known about the hazards of asbestos, and should have been more diligent in protecting its employees from needless exposure.

The suit also alleges that the various defendants could have used asbestos substitutes in their products, but did not.

It has also been alleged that some, or all of the defendants - which were not named publicly - may have destroyed documents and certain evidence, which would have proven Kot's claims.

As a result Kot is seeking at least $550,000 in compensatory damages for pain and suffering, and lost wages. He is also seeking punitive damages representing an undisclosed sum.

Meanwhile, a navy sailor last week was awarded $35.1 million in compensatory damages for exposure to asbestos while serving more than fifty years ago.

John R. 'Jack' Davis was diagnosed, like Kot, with pleural mesothelioma - a disease linked to asbestos exposure. In his suit, Davis claimed that he was exposed to asbestos-covered pipes and vales during his tour of duty in the U.S. Navy, as well as his private-sector career.

The Navy, along with a number of un-named defendants, will have to pool in order to pay the lion's share of the award, 85.8 per cent. The remaining 14.2 per cent of the award is the responsibility of Leslie Controls of Florida, and Warren Pumps of Massachusetts, which will each pay 7.1 per cent. The latter two companies were identified as having supplied asbestos-based material to the Navy.

The verdict, delivered by a jury in Los Angeles Superior Court after a five-week trial, came after deliberations of less than a day, and breaks down to $100,000 for economic damages, $25 million for Mr. Davis' pain and suffering, and a further $10 million for his wife.

Pleural mesothelioma is a deadly cancer that is linked exclusively to the inhalation of asbestos particles in the air. Various countries have implemented an outright ban of asbestos use, something the United States tried but failed, after the ban was overturned in the courts. As a result, there are still products which contain asbestos, such as brake linings.

The incubation period is a long one: the lag time between asbestos exposure and the onset of pleural mesothelioma can be anywhere from 20 to 50 years.

Little wonder that Mr. Kot and Mr. Davis, identified above, litigated so long after exposure. Both men were diagnosed in 2007, decades after the fact.

It is a reasonable expectation there will be many more to come.

SOURCE

Mesothelioma still needs more attention, research funding

Regarding the Oct. 15 front page article, ''Cancer death rates declining'': The death rate for mesothelioma, an extremely painful cancer in which membrane cells lining the chest or abdomen become malignant and proliferate uncontrollably, is on the rise.

Mesothelioma, caused by asbestos exposure, is almost always fatal. The life expectancy is 12.3 months with treatment and 9.2 months without. In fact, according to the National Center for Health Statistics, Pennsylvania ranks third in the nation in the mortality rate for mesothelioma.

Mesothelioma's latency is as long as 50 years, so millions of Americans who were exposed in the past five decades are at risk. And, given the current levels of asbestos exposure, it is inevitable that Americans will continue to be diagnosed for decades. The only hope is research to develop effective treatment.

Much has been accomplished with limited, private funding. It is time for the federal government to help find a cure. With facts like these, it is extremely distressing to know that less than 3 percent of cancer research dollars go to mesothelioma research. Wake up, Lehigh Valley; not all cancers or cancer death rates are on the decline.

SOURCE

LORDS' 'ILLNESS' RULING SLAMMED BY VICTIM

A retired dockyard worker who developed scars on his lungs after working with asbestos has attacked a House of Lords decision to end compensation for people with the condition.Ken Peach, aged 75, of Beacon Park, said the Law Lords ruling on pleural plaques - scars on the lungs usually caused by exposure to asbestos - is "disgusting".

The condition can lead to fatal diseases including malignant mesothelioma and other forms of lung cancer.

The House of Lords yesterday ruled that pleural plaques was not a disease, ending future claims.

The landmark decision could affect hundreds of people in Plymouth, which is a 'hotspot' for asbestos-related conditions.

SOURCE

Mr Peach joined unions, solicitors and Plymouth MP Linda Gilroy in criticism of the ruling.

The pensioner, who received a Government payout in 2001 after developing pleural plaques, said: "It's disgusting and I feel very sorry this decision was made.

"I have a five per cent chance of the scars on my lungs developing into something more serious. It's a horrible feeling to know it's there; it worries me."

Mr Peach joined Devonport Dockyard in 1952 when he was just 20, working as a joiner. His job involved fitting and ripping out layers of asbestos from submarines docked for routine maintenance.

Plymouth MP Linda Gilroy, who sits on the All-Party Parliamentary Group for Asbestos, said Plymouth has one of the country's highest rates of asbestos-realted conditions.

"This decision is a huge disappointment," she said.

"There will soon be a meeting of the all-party group and we will look at this issue, as well as many others surrounding asbestos-related conditions, and will endeavour to lend as much support to it as we can."

The latest figures show 320 people dying from mesothelioma caused by asbestos between 1985 and 2004.

Cases are expected to peak between 2011 and 2015, as the condition takes between 30 to 40 years to emerge.

John Messham, head of the occupational disease department at Bond Pearce in Plymouth, said the firm has seen around 200 successful cases for pleural plaques in the last five years - with pay outs of between £3,500 and £7,000.

He said: "I could say the House of Lords has failed to recognise the anxiety caused by pleural plaques.

"It's the right decision for insurers but not the many thousands of people across the country who have the condition, for who it will be a devastating blow."

He added around 30 Plymothians' cases would have to be dropped following the announcement.

Derek Simpson, joint general secretary of Unite, said: "This is a harsh decision which will affect thousands of people with pleural plaques now and in the future."

The only three UK areas with higher figures of asbestos-related diseases are Barrow-in-Furness, West Dumbartonshire and North Tyneside.

'Cruel injustice' of axed asbestos pay-outs

FAMILIES and campaigners yesterday condemned the "injustice" of a House of Lords ruling which will end compensation for thousands of workers suffering from an asbestos- related condition.

The judgment removes an established right to compensation, which had existed for 20 years, to allow people with pleural plaques - scars on the lungs - to claim damages.

Those affected claim these scars can develop into more serious conditions including cancer. However, their longstanding right to compensation was subject to an appeal by insurance companies, with the Court of Appeal finding in the companies' favour last year that pleural plaques was not a disease.

Unions appealed this and the controversial case went before the Lords yesterday, where the Court of Appeal decision was upheld.

The five Law Lords who heard the cases agreed that the appeals should be dismissed because the law does not offer compensation to victims of injuries which cause no or trivial damage.

Activists have now pledged to ask the Scottish Parliament to bring in new legislation in Scotland to reverse the Lords' judgment.

They have prepared a bill, which has cross-party support, and will submit it to Kenny MacAskill, the justice secretary, urging him to change the law north of the Border.

Harry McCluskey, secretary of Clydeside Action on Asbestos, which represents hundreds of families of former shipyard and factory workers, said: "The judgment has gone against the workers who have to live with the condition with the appalling fear that it could develop into mesothelioma [a form of cancer].

"It is a ridiculous judgment and the injustice is cruel."

Ian Tasker, of the STUC, said: "The STUC has supported asbestos groups and we are extremely disappointed that this is another injustice to the victims of asbestos.

"The legal system pays too much attention to business and it doesn't pay enough attention to the victims."

Pleural plaques can, over time, make breathing difficult and, in some cases, can be accompanied by the development of serious respiratory diseases including mesothelioma and lung cancer.

Previously, victims could claim between £6,000 to £10,000 if they had pleural plaques and more if they developed mesothelioma.

Bill Kidd, an SNP MSP and Robert Brown, a Liberal Democrat MSP, backed the move to introduce new legislation at the Scottish Parliament.

Mr Kidd said: "This decision by the House of Lords flies in the face of common sense and has to be rectified as quickly as possible."

Bill Butler, a Labour MSP, added: "[The ruling] comes down on the side of the employers and insurance companies and disregards the legitimate case of victims and their families."

Solicitor-advocate Frank Maguire, of Thompsons Solicitors, a leading campaigner for asbestos victims, said: "This judgment will only diminish respect for the law by showing how divorced it can be from reality."

SOURCE

Is Vitamin C a Viable Treatment for Cancer?

Vitamin C whether intravenous or oral is one of the most prevalent types of alternative and complimentary cancer therapies. Yet, this nutrient is still considered “controversial” by mainstream oncology. Since two time Nobel Prize winner (in chemistry and peace) Dr. Linus Pauling advocated its use in cancer starting in the late 1970’s, evidence to its efficacy has been quietly and steadily mounting.

Humans Do Not Make Vitamin C

Almost all animals and plants synthesize their own vitamin C except humans and a small number of other animals, including, apes, guinea pigs, the red-vented bulbul, a fruit-eating bat and a species of trout.

Vitamin C and Cancer - Early Work

Pure L-ascorbic acid (vitamin C) was first prepared in 1928 by the Nobel prize winning biochemist Albert Szent-Gyorgyi and in 1932 it was shown that this substance was vitamin C. In 1954 and 1959 Dr. W. J. McCormick, a Canadian physician, hypothesized that cancer is a collagen disease, secondary to a vitamin C deficiency. His theory was based on the fact that collagen is the “mortar” that binds cells together and if cells stick together, tumors would have a more difficult time breaking away and metastasizing. This concept was expanded upon when, in 1966, Dr. Ewan Cameron wrote a book entitled “Hyaluronidase and Cancer.” In it he pointed out that the ground substance or “intercellular cement” that binds cells of normal tissues contains various molecules that strengthen it including glycosaminoglycans and fibrils of collagen. Dr. Cameron discussed how tumors can produce enzymes that breakdown these molecules (i.e. hyaluronidase and collagenase).

Linus Pauling, Ph.D. (chemistry) had been interested in vitamin C for many years and had written previously how people required large amounts of vitamin C (1). Working with Dr. Cameron, Dr. Pauling pointed out that Vitamin C could: A) stimulate normal cells to produce increased amounts of a hyaluronidase inhibitor and; B) increase the number of collagen fibrils made (2). Based on these theories, Drs. Pauling and Cameron embarked on a number of studies to test the efficacy of vitamin C in cancer patients.

Pauling and Cameron Studies Find Improvement in Survival and Quality of Life

In 1976, Drs. Pauling and Cameron reported the survival times of 100 terminal cancer patients who were given supplemental ascorbate (10 grams/daily intravenously) and those of a control group of 1,000 patients of similar status treated by the same clinicians in the same hospital (Vale of Leven Hospital in Scotland) who had been managed identically except for the ascorbate. The 1,000 controls were matched by sex, age, primary tumor type, and clinical status. By August 10, 1976 all 1,000 of the controls had died while 18 of the 100 ascorbate-treated patients were still living. As of September 15, 1979, five ascorbate treated patients were still alive and “living normal lives.” The 100 acorbate-treated patients lived, on the average, 300 days longer than their matched controls with better quality of life (measured from the time all patients were considered “untreatable”).

A second study was performed in 1978 with 100 new ascorbate-treated patients and 1,000 matched controls (about half of the controls were in the original set) (3). This analysis broke out the improved survival times by cancer type. For each type of cancer there was an improvement in survival.

Mayo Clinic Studies Do Not Show Significant Benefit

Pauling’s and Cameron’s studies were not considered the gold standard in clinical studies. The gold standard was and remains the randomized, prospective, double-blind study in which half the patients are randomized to one arm of a study, half to another arm and neither the patient nor the doctor knows who is getting what.

To test whether ascorbate was effective, Dr. Charles Moertel and his colleagues at the Mayo Clinic conducted two randomized placebo controlled studies of patients each with advanced cancer (published in 1979 and 1985) (4). Patients randomized to the treatment group were given 10 grams of oral ascorbate, and neither study showed significant benefit. (In the first Mayo study, median survival was improved two weeks with the ascorbate group.) Because Moertel’s studies were taken as definitive, ascorbate treatment was considered useless. There were however, at least three significant differences between the Mayo Clinic’s “definitive” studies and those of Drs. Pauling and Cameron.

Mayo Clinic Studies Did Not Replicate the Studies by Pauling and Cameron

Difference #1 - In First Mayo Study Most Patients Were Pretreated With Chemo

The overwhelming majority - 87% (52 of 60 patients) of the patients in the first Mayo study had received chemotherapy before the study began. In contrast, only 4% of the patients in Pauling and Cameron study had received chemo. Pauling wrote, “It is known that cytotoxic chemotherapy damages the immune system and might prevent the vitamin C from being effective, inasmuch as it functions mainly by potentiating this system.(5)”

This is a valid critique. A Pubmed search for vitamin C reveals a large number of peer reviewed medical and scientific journal articles that demonstrate that vitamin C scavenges free radicals when it acts as an antioxidant (6), helps neutralize carcinogenic chemicals such as nitrosamine and nitrites (7), enhances lymphocyte function and mobilization of phagocytes (8), improves natural killer cell activities (9), modulates cell growth and differentiation (10), and enhances IgA, IgG and IgM antibody levels (11). Several of these mechanisms are directly related to the body’s immune system and to cancer resistance. Cytotoxic (cell-killing) chemotherapy is notorious for seriously compromising the patient’s immune system by killing the cells that mediate immunity. (Note: in the 1985 Mayo clinic study, this difference was removed as none of the Mayo patients were administered prior chemotherapy.)

Difference #2 - Pauling and Cameron Administered Intravenous Vitamin C, the Mayo Studies Used Only Oral Vitamin C

A commentary published by doctors from the National Institute of Health (NIH) in 2000 pointed out that there was a second significant difference in study design that may have accounted for the different results in the Mayo Clinic studies (12). The authors explained that intravenous (IV) administration (used by Pauling and Cameron) was superior to oral administration (used by Moertel) in respect to bioavailability of the vitamin. The NIH authors said, “It is now clear that intravenous administration of ascorbate can yield very high plasma levels, while oral treatment does not.” The NIH authors concluded that, “Moertel’s results were not comparable to those of Cameron, as ascorbate was given orally and not intravenously. In retrospect, the route of administration may have been key.”(13)

This observation was repeated in another peer reviewed paper published in 2004 in the Annals of Internal Medicine which stated “Because efficacy of vitamin C treatment cannot be judged from clinical trials that use only oral dosing, the role of vitamin C in cancer treatment should be reevaluated.” (14)

Difference #3 - In Pauling’s and Cameron’s Studies, Vitamin C Therapy Continued For the Life of the Patient

And yet a third difference with the Mayo Clinic study was that vitamin C administration was discontinued immediately after a patient could no longer take oral medications or there was progression of the disease. Apparently, in the Pauling and Cameron studies the IV doses continued regardless of the patient’s changing status. Vitamin C was provided during the life of the patient. However, in Moertel’s studies, because it was administered orally, vitamin C was discontinued in a large number of patients whenever there was a sign of worsening. According to writer Ralph Moss, “Because of the odd departure from Cameron’s protocol, patients in the treatment arm of the experiment (in Moertel’s second study) received vitamin C for a median time of only 10 weeks. None of the Mayo patients died while receiving it. Their deaths occurred after the vitamin had been taken away from them.”(15)

Was the Goal of the Mayo Studies to Replicate Pauling and Cameron’s Work or Denounce It?

Obviously if the Mayo Clinic studies were designed to test the outcomes of Drs. Pauling and Cameron studies then they should have replicated their methodology of administration (as long as it was scientifically reliable and clinically appropriate). Why didn’t Moertel’s group administer the vitamin intravenously throughout the life of the patient? We don’t know. Any one of these discrepancies described above should have been sufficient for a complete reevaluation, but as is so often the case, the cancer establishment had successfully “proved” that a mere vitamin was of no value in cancer and the case was closed. Or was it?

Vitamin C Therapy is Still Used Today

In the intervening 20 years since Moertel’s last study two trends have continued: 1) patients are being administered IV vitamin C in various cancer clinics around the world and many are showing benefit; 2) the overall plausibility of ascorbic acid administered intravenously as a cancer therapy is being better understood by recent insights into clinical pharmacokinetics and its in vitro cancer-specific cytotoxicity.

Clinical Examples from the National Cancer Institute

A reading of Drs. Cameron and Pauling’s book “Cancer and Vitamin C” provides 26 case histories of patients with various cancers who received a benefit from vitamin C including: brain, breast, prostate, bladder, lung, stomach, ovarian cancer, leukemia and mesothelioma. But, since Cameron and Pauling have been considered advocates of vitamin C, here is another more disinterested source. Three case examples come from a peer reviewed article whose authors come from the National Cancer Institute, the National Institutes of Health, and universities. In a March 2006 article entitled “Intravenously administered vitamin C as cancer therapy: three cases” the authors examined clinical details of three cases in accordance with National Cancer Institute (NCI) Best Case Series guidelines (16). Tumor pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In all three cases (metastatic renal cancer, bladder cancer, and lymphoma), vitamin C demonstrated efficacy.

Although these case histories by themselves are insufficient to prove that vitamin C is an effective treatment for cancer, in the words of these authors, these histories “increase the clinical plausibility of the notion that vitamin C administered intravenously might have effects on cancer under certain circumstances.(17)”

Biological Mechanisms of Vitmain C Are Better Understood Today

The number of peer reviewed journal articles continues to grow that describe the clinical pharmacokinetics and in vitro cancer-specific cytotoxicity of vitamin C. In other words, how Vitamin C is absorbed by the body and can kill cancer cells. For example, an article published in the Annals of Internal Medicine set out the pharmacokinetics of intravenous vitamin C (18); another article in the journal Nature discussed how vitamin C preferentially killed melanoma cells (19); and there have been several articles in Anticancer Research(20), and Oncology (21) that described how ascorbate killed various other cancer cell lines in vitro.

Vitamin C and Collagen

You may recall that Drs. Cameron and Pauling pointed out that Vitamin C could increase the number of collagen fibrils made. In the last 20 years biochemists have described the molecular basis of scurvy and in doing so have helped us understand how vitamin C and collagen are related. Apparently vitamin C plays a role in collagen metabolism by acting as a cofactor in the enzymatic reactions involved in the hydroxylation of praline and lysine. Without this hydroxylation, proper aligned stable helices of the alpha chains are not formed, so the procollagen that is formed is unstable and degraded (22).

Vitamin C May Prolong Life

Vitamin C has many roles that may be associated with fighting cancer including: acting as an anti-oxidant and scavenging free radicals, supporting the various immune cells, modulating cell growth and differentiation, helping to synthesize carnitine which is essential for the transport of fat to mitochondria, and possibly even strengthening collagen. The mounting evidence does suggest that Drs. Pauling and Cameron were right and that vitamin C is a benefit to cancer patients. We will conclude, therefore, with their words, “Vitamin C is not a miraculous cure for cancer, but…it significantly prolongs the life of the cancer patient…We believe that supplemental ascorbate can be of real help to all cancer patients and of quite dramatic benefit to a fortunate few.”(23)

Perhaps our health authorities will recognize the benefit of this “mere” vitamin. But, maybe the issue all along was not the fact that vitamin C is a potentially effective and non-toxic therapy, but rather that drug companies cannot make sufficient profits from it because as a vitamin it is difficult to patent. If this is the case, it would be an example of how economics not medicine decides what therapies are made available for cancer.

SOURCE

LinkWithin